Nuvectis Pharma Overview
- Year Founded
-
2020
- Status
-
Public
- Employees
-
13
- Stock Symbol
-
NVCT
- Share Price
-
$19.39
- (As of Friday Closing)
Nuvectis Pharma General Information
Description
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
Contact Information
Website
www.nuvectis.comCorporate Office
- 1 Bridge Plaza, 2nd Floor
- Suite 275
- Fort Lee, NJ 07024
- United States
Corporate Office
- 1 Bridge Plaza, 2nd Floor
- Suite 275
- Fort Lee, NJ 07024
- United States
Nuvectis Pharma Stock Performance
As of 20-Nov-2026, Nuvectis Pharma’s stock price is $19.39. Its current market cap is $667M with 34.4M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $19.39 | $19.84 | $5.77 - $29.27 | $667M | 34.4M | 206K | -$2.00 |
Nuvectis Pharma Financials Summary
As of 30-Sep-2026, Nuvectis Pharma has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 667,283 | 157,950 | 87,357 | 122,445 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (52,123) | (27,574) | (19,847) | (22,897) |
| Net Income | (50,454) | (26,442) | (19,000) | (22,260) |
| Total Assets | 140,839 | 31,709 | 18,607 | 19,185 |
| Total Debt | 0 | 0 | 0 | 0 |
Nuvectis Pharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Nuvectis Pharma Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Nuvectis Pharma Comparisons
Industry
Financing
Details
Nuvectis Pharma Competitors (6)
One of Nuvectis Pharma’s 6 competitors is CTI BioPharma, a Formerly VC-backed company based in Seattle, WA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| CTI BioPharma | Formerly VC-backed | Seattle, WA | ||||
| Sutro Biopharma | Formerly VC-backed | South San Francisco, CA | ||||
| ADC Therapeutics | Formerly VC-backed | Epalinges, Switzerland | ||||
| Ability Pharma | Private Equity-Backed | Cerdanyola, Spain | ||||
| OncoResponse | Venture Capital-Backed | Houston, TX |
Nuvectis Pharma Patents
Nuvectis Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026226638-A1 | Methods of treating cancer using src kinase inhibitors | Pending | 23-Apr-2025 | ||
| EP-4805354-A1 | Crystalline forms of the tyrosine kinase inhibitor ecf506 | Pending | 08-Nov-2023 | ||
| WO-2025101861-A1 | Crystalline forms of the tyrosine kinase inhibitor ecf506 | Inactive | 08-Nov-2023 | ||
| EP-4805355-A1 | Crystalline salt forms of the tyrosine kinase inhibitor ecf506 | Pending | 08-Nov-2023 | ||
| WO-2025101874-A1 | Crystalline salt forms of the tyrosine kinase inhibitor ecf506 | Inactive | 08-Nov-2023 | C07D487/04 |
Nuvectis Pharma Signals
Nuvectis Pharma ESG
Risk Overview
Risk Rating
Updated November, 17, 2026
30.07 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Nuvectis Pharma FAQs
-
When was Nuvectis Pharma founded?
Nuvectis Pharma was founded in 2020.
-
Where is Nuvectis Pharma headquartered?
Nuvectis Pharma is headquartered in Fort Lee, NJ.
-
What is the size of Nuvectis Pharma?
Nuvectis Pharma has 13 total employees.
-
What industry is Nuvectis Pharma in?
Nuvectis Pharma’s primary industry is Drug Discovery.
-
Is Nuvectis Pharma a private or public company?
Nuvectis Pharma is a Public company.
-
What is Nuvectis Pharma’s stock symbol?
The ticker symbol for Nuvectis Pharma is NVCT.
-
What is the current stock price of Nuvectis Pharma?
As of 20-Nov-2026 the stock price of Nuvectis Pharma is $19.39.
-
What is the current market cap of Nuvectis Pharma?
The current market capitalization of Nuvectis Pharma is $667M.
-
Who are Nuvectis Pharma’s competitors?
CTI BioPharma, Sutro Biopharma, ADC Therapeutics, Ability Pharma, and OncoResponse are some of the 6 competitors of Nuvectis Pharma.
-
What is Nuvectis Pharma’s annual earnings per share (EPS)?
Nuvectis Pharma’s EPS for 12 months was -$2.00.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process